The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach
Abstract Background Congestive heart failure has reached pandemic levels, and left-ventricular assist devices (LVAD) are increasingly used to treat refractory heart failure. Infection is a leading complication of LVADs. Despite numerous reports (most being retrospective), several knowledge gaps pert...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Antimicrobial Resistance and Infection Control |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13756-024-01503-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850254102240428032 |
|---|---|
| author | Matthew Ficinski Jennifer West Shannon Glassman Katrina Wojciechowski Jennifer Gutowski Maryrose Laguio-Vila Scott Feitell Emil Lesho |
| author_facet | Matthew Ficinski Jennifer West Shannon Glassman Katrina Wojciechowski Jennifer Gutowski Maryrose Laguio-Vila Scott Feitell Emil Lesho |
| author_sort | Matthew Ficinski |
| collection | DOAJ |
| description | Abstract Background Congestive heart failure has reached pandemic levels, and left-ventricular assist devices (LVAD) are increasingly used to treat refractory heart failure. Infection is a leading complication of LVADs. Despite numerous reports (most being retrospective), several knowledge gaps pertaining to the epidemiology and burden of an LVAD-associated infection (LVADi) remain. We sought to address these gaps using a prospective, case-control design. Methods All patients who received an LVAD from November 1, 2018 to August 31, 2023 (n = 110) were included and prospectively monitored until death. Data were extracted from clinical encounters and medical records in real-time or near real-time and imported to Excel and REDcap electronic data capture tools. An LVADi was ascertained using definitions from the mechanical circulatory support academic research consortium in conjunction with and the U.S. National Health Safety Network. All meeting those definitions were included as ‘cases.’ Patients with no LVADi were controls. Excess lengths-of-stays (LOS) and direct costs were calculated from billing records using a commercial cost accounting software platform (Strata®, Chicago, IL). Results The amount of healthcare contact before implantation and discharge to a rehabilitation or skilled nursing facility instead of home were the primary risks for infection, resulting in mean excesses of 25 hospital and 60 antibiotic-days and $43,000 per event. One-third occurred > 1 year after implantation. 35% developed > 1 infection. Gram-negative, fungal, and antimicrobial-resistant organisms predominated deep or repeat infections. 7.2% developed ≥ 3 infections. Organisms became increasingly antimicrobial resistant with subsequent infections, leading to extensive or pan-drug resistance in 4.5% of patients. The burden of an LVADi was 1862 excess hospital days, 3960 excess antibiotic days, and $3.4 million. Conclusions Patients with LVADis had significant increases in costs, LOS, readmissions, and antibiotic usage. Antimicrobial resistance varied directly with the number of repeat infections and antibiotic exposure. Identification of factors associated with LVADi, and quantification of the burden of LVADi can inform prevention efforts and lead to reduced infection rates. As preventing infections in the first place is also important for limiting the emergence of antimicrobial resistance, we offer strategies to avoid LVADis. Trial registry Not applicable. |
| format | Article |
| id | doaj-art-e042d6268eb44151a7fde26992fc29f5 |
| institution | OA Journals |
| issn | 2047-2994 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Antimicrobial Resistance and Infection Control |
| spelling | doaj-art-e042d6268eb44151a7fde26992fc29f52025-08-20T01:57:12ZengBMCAntimicrobial Resistance and Infection Control2047-29942024-12-011311710.1186/s13756-024-01503-4The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approachMatthew Ficinski0Jennifer West1Shannon Glassman2Katrina Wojciechowski3Jennifer Gutowski4Maryrose Laguio-Vila5Scott Feitell6Emil Lesho7Infectious Diseases Department, Rochester Regional HealthInfection Prevention, Rochester Regional HealthAccounting Department, Rochester Regional HealthMedical Department, Rochester Regional HealthInfection Prevention, Rochester Regional HealthInfectious Diseases Department, Rochester Regional HealthCardiology Department, Rochester Regional HealthInfectious Diseases Department, Rochester Regional HealthAbstract Background Congestive heart failure has reached pandemic levels, and left-ventricular assist devices (LVAD) are increasingly used to treat refractory heart failure. Infection is a leading complication of LVADs. Despite numerous reports (most being retrospective), several knowledge gaps pertaining to the epidemiology and burden of an LVAD-associated infection (LVADi) remain. We sought to address these gaps using a prospective, case-control design. Methods All patients who received an LVAD from November 1, 2018 to August 31, 2023 (n = 110) were included and prospectively monitored until death. Data were extracted from clinical encounters and medical records in real-time or near real-time and imported to Excel and REDcap electronic data capture tools. An LVADi was ascertained using definitions from the mechanical circulatory support academic research consortium in conjunction with and the U.S. National Health Safety Network. All meeting those definitions were included as ‘cases.’ Patients with no LVADi were controls. Excess lengths-of-stays (LOS) and direct costs were calculated from billing records using a commercial cost accounting software platform (Strata®, Chicago, IL). Results The amount of healthcare contact before implantation and discharge to a rehabilitation or skilled nursing facility instead of home were the primary risks for infection, resulting in mean excesses of 25 hospital and 60 antibiotic-days and $43,000 per event. One-third occurred > 1 year after implantation. 35% developed > 1 infection. Gram-negative, fungal, and antimicrobial-resistant organisms predominated deep or repeat infections. 7.2% developed ≥ 3 infections. Organisms became increasingly antimicrobial resistant with subsequent infections, leading to extensive or pan-drug resistance in 4.5% of patients. The burden of an LVADi was 1862 excess hospital days, 3960 excess antibiotic days, and $3.4 million. Conclusions Patients with LVADis had significant increases in costs, LOS, readmissions, and antibiotic usage. Antimicrobial resistance varied directly with the number of repeat infections and antibiotic exposure. Identification of factors associated with LVADi, and quantification of the burden of LVADi can inform prevention efforts and lead to reduced infection rates. As preventing infections in the first place is also important for limiting the emergence of antimicrobial resistance, we offer strategies to avoid LVADis. Trial registry Not applicable.https://doi.org/10.1186/s13756-024-01503-4LVADCostLength of stayAntibiotic stewardshipBurden |
| spellingShingle | Matthew Ficinski Jennifer West Shannon Glassman Katrina Wojciechowski Jennifer Gutowski Maryrose Laguio-Vila Scott Feitell Emil Lesho The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach Antimicrobial Resistance and Infection Control LVAD Cost Length of stay Antibiotic stewardship Burden |
| title | The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach |
| title_full | The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach |
| title_fullStr | The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach |
| title_full_unstemmed | The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach |
| title_short | The burden of left ventricular assist device (LVAD) infections on costs, lengths of stay, antimicrobial consumption and resistance: a prospective case control approach |
| title_sort | burden of left ventricular assist device lvad infections on costs lengths of stay antimicrobial consumption and resistance a prospective case control approach |
| topic | LVAD Cost Length of stay Antibiotic stewardship Burden |
| url | https://doi.org/10.1186/s13756-024-01503-4 |
| work_keys_str_mv | AT matthewficinski theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT jenniferwest theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT shannonglassman theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT katrinawojciechowski theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT jennifergutowski theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT maryroselaguiovila theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT scottfeitell theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT emillesho theburdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT matthewficinski burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT jenniferwest burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT shannonglassman burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT katrinawojciechowski burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT jennifergutowski burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT maryroselaguiovila burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT scottfeitell burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach AT emillesho burdenofleftventricularassistdevicelvadinfectionsoncostslengthsofstayantimicrobialconsumptionandresistanceaprospectivecasecontrolapproach |